We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04484363
Expanded Access Status : No longer available
First Posted : July 23, 2020
Last Update Posted : September 30, 2022
Sponsor:
Information provided by (Responsible Party):
Takeda

Brief Summary:

Participants in the expanded access program are adults with higher-risk myelodysplastic syndromes who have no other treatment options available.

The main aim of this program is to allow participants to have access to pevonedistat before FDA approval.

This program will take place in the United States.


Condition or disease Intervention/treatment
Myelodysplastic Syndromes Drug: Pevonedistat Drug: Azacitidine

Detailed Description:

This is an expanded access program in which the drug being tested is called pevonedistat, which is used in combination with azcitidine. This study will provide expanded access of pevonedistat (in combination with azacitidine) for the first-line treatment to participants with HR-MDS and option of real world data (RWD) collection for the benefit of future participants.

All participants will receive azacitidine via intravenous or subcutaneous route in combination with pevonedistat intravenous infusion.

This multi-center trial will be conducted in the United States. Participant will continue treatment until benefit is no longer derived from the treatment (that is, until disease progression, or treatment is no longer tolerable), the benefit-risk no longer favors the individual, an appropriate alternative therapy becomes available, the participant chooses to discontinue the treatment, or pevonedistat becomes commercially available.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: Expanded Access Program: Pevonedistat (in Combination With Azacitidine) for the First-line Treatment of Higher Risk Myelodysplastic Syndromes



Intervention Details:
  • Drug: Pevonedistat
    Pevonedistat 20 milligram per square meter (mg/m^2), intravenous infusion, on Days 1, 3, and 5 of repeated 28-day cycles.
  • Drug: Azacitidine
    Azacitidine 75 mg/m^2, intravenous or subcutaneous infusion, on Days 1 to 5, Days 8 and 9 of repeated 28-day cycles or Days 1 through 7 of repeated 28-day cycles.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  1. Has morphologically confirmed diagnosis of MDS.
  2. With MDS have one of the following Prognostic Risk Categories, based on the Revised International Prognostic Scoring System (IPSS-R)

    • Very high (greater than [>] 6 points).
    • High (>4.5-6 points).
    • Intermediate (>3-4.5 points): a participant determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of greater than or equal to (>=) 5 percent (%) bone marrow myeloblasts.
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
  4. Has never been treated with Azacitidine, or, has been treated with Azacitidine, two or fewer cycles of Azacitidine have been administered, and has not relapsed while being treated with Azacitidine or failed Azacitidine treatment.

Exclusion Criteria:

  1. Has previous treatment for HR MDS with chemotherapy or other antineoplastic agents including hypomethylating agent (HMAs) such as decitabine or more than two cycles of azacitidine.

    • Previous treatment with lenalidomide is permitted, except that lenalidomide may not be given within 8 weeks of first dose of drug.

  2. Has acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
  3. Has either clinical evidence of or history of central nervous system involvement by acute myelogenous leukemia (AML).
  4. Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
  5. Has prothrombin time (PT) or activated partial thromboplastin time (aPTT) >1.5*upper limit of normal (ULN) or active uncontrolled coagulopathy or bleeding disorder. Participants therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded from enrollment.
  6. Has known hepatitis B surface antigen seropositivity, or known or suspected active hepatitis C infection. Note: Participants who have isolated positive hepatitis B core antibody (that is, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Participants who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.
  7. Has known hepatic cirrhosis or severe preexisting hepatic impairment.
  8. Has known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), and/or myocardial infarction within 6 months before first dose, or severe pulmonary hypertension.
  9. Has treatment with strong cytochrome P 3A (CYP3A) inducers within 14 days before the first dose of pevonedistat.

    .


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04484363


Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
Additional Information:
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT04484363    
Other Study ID Numbers: Pevonedistat-5005
First Posted: July 23, 2020    Key Record Dates
Last Update Posted: September 30, 2022
Last Verified: September 2022
Keywords provided by Takeda:
Drug Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Preleukemia
Myelodysplastic Syndromes
Syndrome
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Azacitidine
Pevonedistat
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors